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Abstract: Recent efforts have made in order to novel therapeutic approaches to reduce the heavy 
cardiovascular burden. The use of cell therapy and applying stem cell-based therapies has received 
much attention; of particular interest are adipose-derived mesenchymal stem cells (ADSCs). The 
present review aimed to review the studies which examined and researched various aspects of ADSCs 
to improve cardiac function. A comprehensive review of all articles assessed and discussed the 
application of ADSCs in the improvement of cardiac tissue renewing and cardiomyocytes regeneration 
was planned and conducted by the two reviewers. The initial literature search revealed a total of 153 
articles that, of those, 34 were considered eligible. From the perspective of heart tissue regeneration, 
the inductive role of ADSCs in sensing mechanical stimulation and produce collagen and elastin 
scaffolds, vascularizing cardiac tissue, and exosomes (vesicles derived from ADSCs) in ADSCs‐
mediated myocardial protection has indicated. In the process of ADSCs differentiation to 
cardiomyocyte- like cells, the role of various targeted pathways have been identified that can be 
influenced by different elements such as TGF-beta1, phorbol myristate acetate, Angiotensin II, Rho-
associated kinases, 5-Azaytidine, Sodium valproate, fibrin scaffold and trichostatin A have been 
highlighted. In the final, from a therapeutic point of view, the effectiveness of ADMSCs differentiation 
to cardiomyocytes as improving left ventricular functional state has been discussed. Summarizing the 
studies confirms a significant improvement in cardiac function following direct application of ADSCs 
or their transformation to cardiomyocytes by stimulating or inhibiting various cellular pathways leading 
reducing oxidative stress and inflammatory bed, reducing cardiomyocyte apoptosis, attenuating cardiac 
fibrosis, reducing the infiltration of immune cells and collagen deposition, and enhancing angiogenesis.   
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1. Introduction 
Improving live expectancy, as well as reducing disability, is the main goal for clinicians 
dealing with chronic life-threatening or acute debilitating diseases. Conventional treatments 
fail in many cases and, therefore, do not succeed in reducing the heavy burden of the diseases  
[1,2]. In this regard, cardiovascular disease, as the most common cause of morbidity and 
disability in the world, is at the forefront of diseases that, despite the many successes in their 
https://doi.org/10.33263/BRIAC111.84468456  
 https://biointerfaceresearch.com/ 8447 
treatment, continue to fall victim [3]. Even with unfavorable life patterns and sedentary 
lifestyles, we are faced with an upward trend in these diseases and their adverse consequences  
[4]. Therefore, recent efforts have made in order to novel therapeutic approaches to reduce the 
heavy cardiovascular burden. Accordingly, the use of cell therapy and applying stem cell-based 
therapies has received much attention  [5,6]. Of particular interest are mesenchymal stem cells 
(MSCs)  [7,8]. In this regard, different therapeutic approaches have been described in the 
literature in the use of these types of cells for treatment. In initial experiences, MSCs were 
initially inserted in the bone marrow with the capacity to regenerate bone and to create the 
niche for hematopoietic stem cells, known as bone-marrow mesenchymal stem cells [9,10]. In 
the next attempts, the extraction of such cells from other distinct and specific tissues of the 
body, such as adipose tissue, skin, musculoskeletal tissues, lungs, and even placenta has been 
possible [11]. The main feature of these cells is their high potential in differentiating to other 
specialized tissues, especially connective tissues, and the same feature is used to renew 
damaged tissues and organs [12]. In this regard, different mechanisms have been described for 
MSCs - based therapy. First, MSCs can differentiate into the targeted cell types and contribute 
to regenerate the injured tissue[13]. Second, due to potential secretory role, MSCs can secrete 
various growth factors and cytokines, facilitating cell proliferation, inducing vascularization, 
and angiogenesis [14]. Third, MSCs have immunomodulatory role leading control and 
inhibition of inflammation processes leading tissue injury [15]. Although both adipose-derived 
mesenchymal stem cells (ADSCs)  and bone marrow mesenchymal stem cells (BM-MSCs)  are 
now commonly used for regenerating damaged tissues, ADSCs have more potential 
advantages. First, ADSCs are more accessible commonly from subcutaneous fat tissue or 
supra- and infra-patellar fat pads and by lipoaspirates or adipose tissue biopsy, leading to a 
lower burden of morbidity on patients as well as higher satisfaction [16]. Second, it seems that 
ADSCs have more immune properties leading to lower risk for rejection and also higher 
proliferation rate as compared to BM-MSCs [17]. To access ADSCs from fat tissue, following 
enzymatic digestion process, a stromal vascular fraction can be extracted from the adipose 
tissue consisting a mixture of regenerative cell types and various immune cells, including 
preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, resident monocyte, 
and lymphocytes, but ADSCs make up about 30% of the total mixture extracted [18,19]. 
ADSCs are naturally located in the capillary and perivascular adventitia of large blood vessels 
within adipose tissues and are thought to be derived from pericytes  [20]. The main potential 
of ADSCs is to proliferate to stem cells reservoir in the undifferentiated state during life and 
also to give rise to different types of both mesenchymal cell lines (such as fibrocytes, 
chondrocytes, and osteocytes) and also non- mesenchymal cell lines (such as hepatocytes, 
neuronal, and cardiomyocytes) [21,22]. Based on this ability to regenerate cardiomyocytes, the 
use of these cells has been widely proposed to regenerate myocardial tissue. Moreover, due to 
immunomodulation, meaning, and anti-inflammatory properties of ADSCs, the induction and 
promotion of anti-cardiac ischemic-related processes such as new angiogenesis, tissue 
remodeling, and cell apoptosis are possible. The present review aimed to review the studies 
which examined and researched various aspects of ADSCs to improve cardiac function. 
2. Materials and Methods 
 A comprehensive review of all articles assessed and discussed the application of 
ADSCs in the improvement of cardiac tissue renewing and cardiomyocytes regeneration was 
planned. The primary search was conducted according to the main keywords including “heart”, 
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“cardiac function”, “myocardium”, “cardiomyocyte”, and “adipose-derived mesenchymal stem 
cell” using different databases including PubMed, MEDLINE, SCOPUS, Google Scholar, and 
Cochrane Library. The searching was conducted by the two reviewers, which blinded each 
other, and finally, their evaluation results were summarized. Eligibility criteria included 
English-language papers with full-text availability, including both animal and human models, 
in vivo and in vitro assessments. Exclusion criteria consisted of the clinical or experimental the 
predominant pathologies except for the cardiovascular system, multiple publications of a single 
trial, case studies, or reviews. The initial literature search revealed a total of 153 articles that 
of those, 34 were considered eligible and included in this review (Table 1). Data from all papers 
deemed relevant was extracted then independently reviewed by investigators. 
Table 1. Summary of the studies. 
Author, year Type of study Target cells/disease Main issue Main results 
Bagheri, 2020 
[34] 
Exp./in vitro Differentiation of 




5-Azaytidine can induce hADSCs to 
differentiate into cardiomyocytes. 
Bao, 2020  
 [27] 
Exp./in vitro Cardiac transplantation  Tissue 
regeneration  
Toll-Like Receptor 3 activator 
preconditioning enhances modulatory 
function of ADMSCs in heterotopic 
heart transplantation 






Therapy ADMSCs can promote the resolution 
of  cardiac  inflammation after 
ischemia-reperfusion via enhancing 
efferocytosis of neutrophils 






Therapy Cardio-renal exosomes deliver miR-
1956 and activate paracrine 
proangiogenic VEGF signaling in 
ADMSCs used for cardiac 
regeneration after myocardial 
infarction 






Therapy ADMSCs therapy could not improve 
myocardial perfusion, functional 







Therapy Combined cold water-exosome 
therapy improves myocardial function 
and reduces oxidative and 
inflammatory effects  following 







Therapy Combining ADMSCs and myocardial 
decellularized extracellular matrix has 
synergistic effects on cardiac repair  
Deng, 2019 
 [26] 




Exosomes from ADMSCs 
ameliorate cardiac damage after 
myocardial infarction by activating 
S1P/SK1/S1PR1 signaling and 








Exosomes derived from miR-146a-
modified ADMSCs attenuate 
myocardial damage via down-
regulation of early growth response 







Therapy Transplantation of ADMSCs resulted 
in smaller infarcts and 
rescued cardiac function by improving 
left ventricular function and reducing 
inflammation and apoptosis 





Sodium valproate can increase 
cardiomyogenesis in ADMSCs 
Zhang, 2018 
 [57] 
Exp./in vitro Differentiation of 




ADMSCs differentiation to 
cardiomyocyte can be enhanced by 
TGF-β1 effect on increased 
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Author, year Type of study Target cells/disease Main issue Main results 
phosphorylation of the Smad signaling 
pathway 






Therapy Scar size reduction and recovery of 
left ventricular function after 







Therapy Improving systolic and diastolic 
function by implantation of allogeneic 
ADMSCs in cardiac tissue 
Morrissett, 2018 
 [24] 
Exp./in vitro Vascular tissue repair Tissue 
regeneration  
Combining ADMSCs  with ventricular 
cardiomyocytes facilitate the 
formation of 
vascularized cardiac tissues 
Bagheri, 2018 Exp./in vitro Differentiation of 




 Fibrin scaffold with a compressive 
stress of 107.74 kPa allows a higher 
differentiation of ADMSCs into 
cardiomyocyte-like cells treated with 
50 μM 5-Aza. 
Bagheri, 2018 Exp./in vitro Differentiation of 





of fibrin scaffold and trichostatin A 
for differentiation of ADMSCs  







Therapy ADMSCs can attenuate cardiac 







Therapy Exosomes ADMSCs  protect the 
myocardium against Injury through 
Wnt/β-Catenin signaling pathway 
Wystrychowski, 
2016  [33] 
Exp./in vitro Differentiation of 




Epicardial ADMSCs  has higher 
cardiomyogenic potential as compared 







Therapy Melatonin facilitates ADMSCs  to 
repair the murine infarcted heart via 







Therapy ADMSCs  is effective in mitigating 
cardiac damage by promoting 
angiogenesis, decreasing the 








Therapy Priming of ADMSCs with curcumin 
improve tolerance to oxidative stress 
injury and resulted in enhancement of 








Therapy Intramyocardial injection of ADMSCs 
combining with ghrelin inhibits 
cardiomyocyte apoptosis, reduced 
fibrosis, and 
improved cardiac function through 
PI3K/Akt pathway  
Zhao, 2014 
 [32] 
Exp./in vitro Differentiation of 




Rho-associated protein kinases 
enhance ADMSCs differentiation into 
cardiomyocytes 






Therapy  Improving left ventricular function 
and ventricular dilatation remodeling 
by differentiating ADMSCs to 







Therapy Transplantation of ADMSCs resulted 
in smaller infarcts and 
improved cardiac function 
Song, 2013 
 [31] 
Exp./in vitro Differentiation of 




Angiotensin II can induce ADSCs into 
cardiomyocyte-like cells 
Li , 2013 
 [30] 




High capacity of CD73+ ADMSCs 








Therapy Rosuvastatin enhances the therapeutic 
efficacy of ADSCs for MI via 
PI3K/Akt and MEK/ERK pathways 
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Author, year Type of study Target cells/disease Main issue Main results 
Chang, 2012 
 [29] 
Exp./in vitro Differentiation of 




Phorbol myristate acetate 








Therapy Improving left ventricular function by 
administering ADMSCs  directly to 
the myocardium 






Therapy Combining Atorvastatin 
with ADMSCs improve 








ADSCs sense mechanical stimulation 
and produce collagen and elastin, 







Therapy Combining sildenafil and ADMSCs 
more improve left ventricular function 
and angiogenesis   
Gwak, 2009 
 [28] 
Exp./in vitro Differentiation of 




TGF-beta1 can induce ADMSCs 
cardiomyogenic differentiation 
3. Results and Discussion 
The studies reviewed with the goal of assessing the role of ADSCs in the improvement 
of cardiac function can be categorized into three subgroups according to the study design and 
target issue as 1) experimental in-vitro studies with the focus on the role of ADSCs in heart 
tissue regeneration; 2) experimental in-vitro studies with the aim of assessing the pathways and 
mediators for the transformation of ADSCs to specific heart cells; and 3) experimental animal 
modeling study (only one study included human model) assessing the therapeutic efficacy of 
ADSCs in a clinical setting. In this regard, our review focuses on the details of each subcategory 
separately.  
3.1. ADSCs and cardiac tissue regeneration. 
The ability of ADSCs in tissue regeneration has been primarily proposed by Colazzo et 
al. in 2011 [23]. They showed that ADSCs could sense mechanical stimulation and produce 
collagen and elastin, leading to improving heart valve tissue. This process was mediated by the 
upregulation of COL3A1 gene followed by producing collagen and elastin cross-linking and 
also uniformly populated collagen scaffolds shortly after ADSCs induction. In the next effort, 
as shown by Morrissett et al. in 2018 [24], Combining ADMSCs with ventricular 
cardiomyocytes could facilitate the formation of vascularized cardiac tissues, and thus the 
application of ADSCs led to promote functional vascular tissue engineering for cardiac 
regenerative goals. Since 2019, the critical role of exosomes for cardiac tissue regeneration was 
highlighted. In this regard, the obtained evidence by Pen et al. in 2019 [25]. They emphasized 
that exosomes (30‐100 nm small membrane vesicles derived from ADSCs) could play a crucial 
role in ADSCs‐mediated myocardial protection. In their study, it was demonstrated that some 
miRNAs (such as miR‐146a) could promote exosome‐mediated cardioprotective effect, and 
therefore, the link between novel miRNAs and exosomes derived from ADSCs in cardiac tissue 
regeneration has been explained. In another study by Deng et al. [26]. And in parallel to the 
previous observation, it was shown that exosomes derived from ADMSCs could 
ameliorate cardiac damage after myocardial infarction by activating S1P/SK1/S1PR1 signaling 
and promoting macrophage M2 polarization. In recent studies, the regenerative role of ADSCs 
as a cardioprotective element, even following cardiac transplantation, has also been revealed. 
In a recent study by Bao et al. in 2020  [27], Toll-Like Receptor 3 activator preconditioning 
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was shown to be an enhancer for the modulatory function of ADMSCs in heterotopic heart 
transplantation. The pointed study could find that ADSCs had the highest efficiency in 
inhibiting lymphocyte proliferation, which was correlated with the upregulation of fibrinogen-
like protein 2, leading to longer survival of cardiac allografts in transplantation.      
3.2. ADSCs and differentiation to cardiac tissue. 
The initial evidence on the pathways responsible for the differentiation of ADMSCs to 
heart cells was presented by Gwak et al. in 2009 by the assessment of the molecular pathways 
for differentiation of ADMSCs to cardiomyocytes. They focused on a specific cytokine (TGF-
beta1) as a mediator the pointed cellular differentiation and could show that TGF-beta1 could 
induce the mRNA expression of cardiac-specific genes helping cardiac myosin heavy chain 
(MHC) and alpha-sarcomeric actin regeneration [28]. Thereafter, Chang et al. in 2012 [29] 
introduced phorbol myristate acetate, a protein kinase C (PKC) activator, as an important 
element for differentiation of ADMSCs into cardiogenic cells. Their experiment could 
successfully show that cardiomyocytes producing by ADMSCs in the induction of phorbol 
myristate acetate led to markedly reducing infarct size, interstitial fibrosis, and apoptotic index 
and ultimately improving cardiac functional state. Further studies could discover more 
mediators and pathways that induced ADSCs differentiation to cardiac tissue. As indicated by 
Li et al. in 2013 [30], CD73+ ADMSCs had the highest capacity among other cellular subtypes 
for differentiation into cardiomyocytes. Song et al. in 2013  [31] introduce Angiotensin II as a 
potential mediator for differentiating ADMSCs to cardiomyocyte-like cells. Zhao et al., in 
2014, in another in-vitro study in 2014  [32] showed that some protein kinases enhance 
ADMSCs differentiation into cardiomyocytes. According to their observations, Rho-associated 
kinases (ROCKs) could control actin cytoskeleton reorganization, the main pathway for the 
production of cardiomyocytes. As an interesting result obtained by Wystrychowski et al. in 
2016  [33], the affinity and potential of ADMSCs for differentiating to cardiomyocytes is 
significantly different in three layers of cardiac tissue. Based on their finding, epicardial 
ADMSCs had higher cardiomyogenic potential as compared with pericardial, and thus this 
finding opened up the prospect of the fact that ADMSCs derived from different adipose tissue 
depots may exert a diverse multi-potency in differentiating to cardiomyocytes. In order to 
facilitate such cellular differentiation, some authors focused their experiments on elements 
inducing and accelerating differentiation of ADMSCs to cardiomyocytes. In this regard, the 
use of 5-Azaytidine[34], Sodium valproate[35], fibrin scaffold[36] and trichostatin A [37]as 
the accelerators for such cellular differentiation was assessed and demonstrated through in-
vitro experiments. However, the pathways involved in this mediating role should be further 
studied.           
3.3. ADMSCs and therapeutics. 
In recent years, special attention has been paid to the effectiveness of ADMSCs 
differentiation to cardiomyocytes or even its direct-injection, especially in combination with 
other therapeutics to improve cardiovascular function. In this regard, combining ADMSCs with 
different cardiac and even non-cardiac drugs could improve cardiac function. A primarily 
shown by Lin et al. in 2010 [38], combining sildenafil and ADMSCs could improve left 
ventricular ejection fraction along with the progression of myocardial-related angiogenesis in 
the background of dilated cardiomyopathy. In a similar animal study by Cai et al. in 2011  [39], 
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applying ADMSCs in combination with atorvastatin as a main cardioprotective statin could be 
more efficient in recovering ischemic cardiac tissue following acute myocardial infarction. In 
an interesting experimental study by Bagno et al. in 2012 [40], administering ADMSCs directly 
to the myocardium could effectively improve left ventricular systolic dysfunction. Zhang et al. 
[41]. In 2013 could firstly describe the pathways through which statins improve cell therapeutic 
effects. According to their experiments, rosuvastatin could promote the therapeutic effect 
of ADMSCs via PI3K/Akt and MEK/ERK pathways in the sample suffering an acute 
myocardial infarction. Later, some studies could also reveal that the direct transplantation of 
ADMSCs could reduce infarct size in ischemic myocardium leading to the improvement of left 
ventricular functional state and  [42] and ventricular dilatation remodeling   [42,43]. On what 
mechanism is also effective in improving cardiac function after ADMSCs transformation, some 
studies were performed. In this regard, the inducing role of ADMSCs transformation or its 
direct implantation on inhibiting cardiomyocyte apoptosis, reduced fibrosis, and 
improved cardiac function through activation of PI3K/Akt pathway  [44-47], improving 
tolerance to oxidative stress injury  [48], mitigating cardiac damage by promoting angiogenesis 
and decreasing the infiltration of immune cells and collagen deposition [49], and repairing 
damaged myocardium by activating the SIRT1 signaling pathway (by melatonin)  [50] have 
been discussed. In recent experimental studies, the protective role exosomes derived from 
ADMSCs to protect the injured myocardium against some destructive tissue pathways such as 
Wnt/β-Catenin signaling pathway has also been studied. However, none of the studies focusing 
therapeutic effects of ADMSCs alone or in combination with other drugs have performed in 
the human level needing expansion of the studies at the level of clinical trials.  
4. Conclusions 
 Reviewing the literature ultimately shows that directly transformation of ADMSCs to 
cardiomyocytes alone, embedded in platelet-rich fibrin, or along with administration of other 
therapeutics such as statins, melatonin, curcumin, or ghrelin can effectively improve left 
ventricular cardiac function by cardiac tissue regeneration. This process can be mediated by 
activation of some molecular pathways such as paracrine proangiogenic VEGF signaling 
pathway, S1P/SK1/S1PR1 signaling pathway (leading) promoting macrophage M2 
polarization, phosphorylation of the Smad signaling pathway, SIRT1 signaling pathway, 
PI3K/Akt pathway, MEK/ERK pathway, or inactivation of some other pathways such as 
growth response factor 1 producing pathway and Wnt/β-Catenin signaling pathway. The effects 
of ADMSCs as a therapeutic inducer on the pointed pathways are ultimately marked by 
reducing oxidative stress and inflammatory bed, reducing cardiomyocyte apoptosis, 
attenuating cardiac fibrosis, decreasing the infiltration of immune cells and collagen deposition, 
and enhancing angiogenesis that all lead to improvement of left ventricular remodeling and 
ejection fraction. Overall, it seems that the described in-vitro and animal studies should be 
evidenced by human-based studies so that its applications can be clinically productive. 
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